Names Elma S. Hawkins to Board of Directors
11 December 2003, 09:05am ET
YONKERS, N.Y.--(BUSINESS WIRE)--Dec. 11, 2003--Advanced Viral
Research Corporation (BB:ADVR) announced today that Elma S.
Hawkins, Ph.D., MBA has been appointed to the Company's Board
of Directors and named a Member of the Executive Management
Committee, effective immediately.
Dr. Hawkins has more than 20 years of business, management,
regulatory and scientific experience in the pharmaceutical and
biotechnology industries. She played a pivotal role in
bringing a number of drugs to the market in the United States
"I am delighted to welcome Dr. Hawkins to the Board. With
over two decades of strong drug development and management
experience, I am confident that Dr. Hawkins' expertise will
strengthen Advanced Viral Research's ability to move its lead
product, AVR118, through clinical trials towards
commercialization," said Eli Wilner, Chairman of Advanced
Viral Research Corporation.
Mentioned Last Change
ADVR 0.21 (Unchanged)
AGEN 10.84 (Unchanged)
Dr. Hawkins will remain Vice Chairman of Antigenics (NASDAQ:
AGEN), a biotechnology company that is working to develop
personalized immunotherapeutics and revolutionary treatments
for cancers, infectious diseases and autoimmune disorders.
Prior to her position at Antigenics, Dr. Hawkins served in a
number of senior positions in corporate development, strategic
planning, and regulatory and clinical affairs at Genzyme
Corporation and Genzyme Tissue Repair. In addition, Dr.
Hawkins held preclinical, clinical and regulatory positions at
Warner-Lambert/Parke-Davis Pharmaceuticals and at the Center
for the Study of Drug Development at Tufts Medical School.
Advanced Viral Research Corp., based in Yonkers, New York, is
a biopharmaceutical firm dedicated to improving patients'
lives by researching, developing and bringing to market new
and effective therapies for viral and other diseases. ADVR's
AVR118 (formerly known as Product R) represents a biopolymer
chemistry that possesses novel immunomodulator activity. This
peptide-nucleic acid, which to date has shown no indication of
human toxicity, appears to stimulate the proinflammatory
responses required to combat viral infections such as AIDS and
human papilloma virus and to dampen aberrant autoimmune-type
inflammatory responses, such as occur in patients with
rheumatoid arthritis. AVR118 is in clinical trials in Israel
for the treatment of cachexia (body wasting) in patients with
For further information regarding Advanced Viral Research
Corp., please visit our website at www.adviral.com .
Note: This news release contains forward-looking statements
that involve risks associated with clinical development,
regulatory approvals, including application to the FDA,
product commercialization and other risks described from time
to time in the SEC reports filed by the Company. AVR118
(Product R) is not approved by the U.S. Food and Drug
Administration or any comparable agencies of any other
countries. There is no assurance that the Company will be able
to secure the financing necessary to continue and/or complete
the clinical trials of AVR118 or satisfy certain other
conditions relating to clinical trials including obtaining
adequate insurance on terms acceptable to the Company. The
Company undertakes no obligation to update or revise the
information contained in this announcement whether as a result
of new information, future events or circumstances or
CONTACT: CWR & Partners
Ronnie Welch or Kelly Cinelli, 508-222-4802
SOURCE: Advanced Viral Research Corporation
Pressing these keys is the same as
clicking their link equivalents. Note: Netscape users don't have to
press enter after the shortcut. Mac users - use the CTRL key.
|Alt 1 [Enter]
|Alt Z [Enter]
||Previous or Older
|Alt X [Enter]
||Next or Newer